1-4 of 4
Jiaojiao Zhang
Close
Sort by
Journal Articles

Real-World Outcomes of Zanubrutinib Monotherapy in Chronic Lymphocytic Leukemia: A Multicenter Retrospective Study

Jing Luo, Jiaojiao Zhang, Ligen Liu, Rong Wei, Yonghua Yao, Min Xu, Jie Xu, Jumei Shi, Jianmin Yang, Jian Hou, Jin Wang, Jian-Qing Mi
Journal: Blood
Blood (2023) 142 (Supplement 1): 6540.
https://doi.org/10.1182/blood-2023-180477
Published: 2023
Journal Articles

Clinical Characteristics and Survival Analysis of Richter Transformation: A Single Center Retrospective Study in China

Jiaojiao Zhang, Jing Luo, Lei Dong, Xiangqin Weng, Jie Xu, Jin Wang, Jian-Qing Mi
Journal: Blood
Blood (2023) 142 (Supplement 1): 6384.
https://doi.org/10.1182/blood-2023-187133
Published: 2023
Journal Articles

The Prognostic Significance of 1-Year Persistent MRD Negativity in Chinese ALL Patients: 5-Year Follow-up Results from RJ-ALL 2014 Trial

Jiayi Ren, Sijie Tang, Weiyang Liu, Xiangqin Weng, Cheng Wang, Lijun Peng, Wenqian Xu, Yuxuan Shang, Jie Hao, Wenyan Yu, Jiaojiao Zhang, Jie Xu, Yuanfang Liu, Weiping Zhang, Jin Wang, Jian-Qing Mi
Journal: Blood
Blood (2023) 142 (Supplement 1): 6057.
https://doi.org/10.1182/blood-2023-189710
Published: 2023
Journal Articles

Dose Escalation of Blinatumomab Is a Better Option for MRD-Positive CR Patients, Results from a Single-Center Real World Study of Blinatumomab for B-Cell Acute Lymphoblastic Leukemia in China

Sijie Tang, Jiayi Ren, Weiyang Liu, Xiangqin Weng, Yongmei Zhu, Cheng Wang, Lijun Peng, Wenqian Xu, Yuxuan Shang, Wenyan Yu, Jiaojiao Zhang, Jie Xu, Yuanfang Liu, Weiping Zhang, Jian-Qing Mi, Jin Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 5885.
https://doi.org/10.1182/blood-2023-189703
Published: 2023